Rezultati pretraživanja
  1. In case you missed it | Which abstracts from will change clinical practice in AML? Our Steering Committee provided their opinions on the practice-changing abstracts presented, available here as a free downloadable resource:

  2. prije 13 sati

    Marketing authorization application validation of KTE-X19 followed promising data from the phase II ZUMA-2 trial investigating its efficacy and safety. Read a summary of the interim results presented at here➡️

  3. 5. velj
  4. 4. velj

    CARTITUDE-1: How is This Different from Others? : Deepu Madduri, MD of discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell…

  5. 4. velj

    Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL : Steven Horwitz, MD of discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the…

  6. 4. velj

    At , , COTA’s VP of Life Sciences, spoke with on the growing understanding & acceptance of and how it is used in research. Hear his insight below as it relates to clinical trials & recent initiatives:

  7. 4. velj
  8. 3. velj

    The Steering Committee members shared the top abstracts from that they believe could have the greatest impact on clinical practice! Follow the link for their comments ➡️

  9. 3. velj

    Read a summary of the results from the dose escalation phase of a first-in-human study of REGN1979 in patients with R/R B-NHL ➡️

  10. 3. velj

    Early relapse in MCL | A short duration of 1st remission was associated with an increased risk of death, irrespective of front-line therapy intensity in patients with mantle cell lymphoma. Read more here:

  11. 3. velj

    My fellow Dr Kat Lewis presently eloquently on aggressive lymphoma highlights from

  12. 3. velj

    Check and download the full CML AN Congress Report summarizing: •Update on stopping CML treatment •Discontinuation of TKIs in children with CML •New drugs for CML, generic Imatinib and other topics •CML Educational session

  13. 31. sij

    CML is truly one of our success stories: ☑️Identification of -ABL ☑️Development of ☑️ Care revolution Globally, however, deep challenges remain. Check our Session summary.

  14. 31. sij

    At Ali Bazarbachi spoke to the about novel prophylactic therapies available before and after transplantation to reduce the risk of . Watch the interview here ➡️

  15. 31. sij

    From - 4 year analysis confirms sustained benefit of time-limited Venetoclax-Rituximab in relapsed/refractory Chronic Lymphocytic Leukemia Abstract here:

  16. 31. sij
    Odgovor korisniku/ci

    No, that was disclosed at . 2 or 3 of those 5 deaths look like they might have been treatment-related

  17. 31. sij

    Maintenance Therapy With CC-486 Extends Survival of Adults With AML

  18. 30. sij

    discussing the HD14 (early unfav Hodgkin) data presented at . 2xescBEACOPP + 2xABVD + RT better PFS than 4xABVD+RT. BUT the unfav group in H10 did just as well without all receiving v intensive chemo.

  19. 30. sij

    New PreClinical Data for its IL-15 Agonist, NKTR-255 : Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read here: 

  20. 30. sij

    Newly posted! Check out our practice aids on from our recently released activity from .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.